Epilepsy is associated with a variety of cognitive, emotional, and pain-related symptoms, such as impaired memory and learning, increased risk of anxiety and depression, and increased pain sensitivity. Unfortunately, these symptoms are generally untreated with typical pharmacological interventions, which tend to target seizure activity (i.e., ictogenesis) and not the subsequent histopathological and behavioural alterations resulting from epilepsy (i.e., epileptogenesis). Evidence has demonstrated that targeting the endocannabinoid system can alleviate seizure symptoms as well as cognitive, emotional, and pain-related impairments independent of epilepsy. However, research examining the use of endocannabinoid-based treatment for these behavioural symptoms when they are associated with epilepsy is sparse. In the following thesis, two animal models of epilepsy, several behavioural assessments, and immunohistochemical techniques are utilized to assess the effectiveness of endocannabinoid-based treatment for epilepsy's interictal symptoms. The findings expand our knowledge and offer encouraging evidence for the usefulness of endocannabinoid-based treatment as an epileptogenesis-targeting pharmacological intervention.
Author Keywords: animal models, endocannabinoid system, histopathological alterations, interictal symptoms, temporal lobe epilepsy, treatment